ArticleCureus2025
Survival Impact of Isocitrate Dehydrogenase (IDH)-Wildtype Histological Versus Molecular Glioblastoma: A Propensity Score-Matched Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecularly diagnosed glioblastoma: clinical presentation and outcomes.Journal of neuro-oncology · 2026Article
- Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis. Molecular classification has redefined GBM subtypes, but survival differences between histological GBM (h-GBM) and molecular GBM (mol-GBM) remain underexplored. This study uses propensity score matching (PSM) to compare survival outcomes, accounting for clinical confounders. Methods A retrospective cohort of isocitrate dehydrogenase (IDH)-wildtype GBM patients was analyzed using 1:1 nearest-neighbor PSM, balancing age (<64 or ≥64 years), O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and radiotherapy (RT) dose. Kaplan-Meier estimates and log-rank tests were used to compare the overall survival (OS) and progression-free survival (PFS) between h-GBM and mol-GBM. Results The matched cohort included 26 h-GBM and 26 mol-GBM patients. Median OS was 15.2 months for mol-GBM vs. 14.2 months for h-GBM (p=0.238). Mol-GBM showed significantly longer PFS (11.8 vs. 8.0 months, p=0.005). In MGMT-unmethylated patients, mol-GBM had superior OS (15.2 vs. 12.7 months, p=0.030) and PFS (13.1 vs. 7.8 months, p<0.001). Higher RT dose (60 Gy/30 fractions) improved OS (22.1 vs. 13.3 months, p=0.010) and PFS (10.8 vs. 8.7 months, p=0.020) in mol-GBM. Conclusion Molecular classification significantly influences GBM prognosis, with mol-GBM demonstrating better PFS and selective OS benefits in MGMT-unmethylated patients. Higher RT doses enhance outcomes, supporting personalized treatment strategies. Validation in larger cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.